Meloxicam

Drugs

Volumn 51, Issue 3, 1996, Pages 424-430

  Noble, S ^a   Balfour, J A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; MELOXICAM; NAPROXEN; PIROXICAM; PROSTAGLANDIN SYNTHASE; TENIDAP;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; DIGESTIVE SYSTEM PERFORATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GUINEA PIG; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; RAT; RECTAL DRUG ADMINISTRATION; REVIEW; RHEUMATOID ARTHRITIS; STOMACH ULCER;

EID: 0029878866     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651030-00007     Document Type: Review

References (43)

1. 1. J.R. Vane R.M. Botting 1995 New insights into the mode of action of anti-inflammatory drugs Inflamm Res 44 1 10 7664022 10.1007/BF01630479 1:CAS:528:DyaK2MXktlKrtbs%3D Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1–10
2. 2. G. Engelhardt R. Bögel C. Schnitzler 1996 Meloxicam: a new NSAID with an improved safety profile through preferential inhibition of COX-2 Biochem Pharmacol 51 21 8 8534264 10.1016/0006-2952(95)02111-6 1:CAS:528:DyaK28Xht1GmtQ%3D%3D Engelhardt G, Bögel R, Schnitzler C, et al. Meloxicam: a new NSAID with an improved safety profile through preferential inhibition of COX-2. Biochem Pharmacol 1996; 51: 21–8
3. 3. Churchill L, Graham A, Shih C-K, et al. Selective inhibition of human cyclooxygenase-2 by meloxicam. Boehringer In-gelheim. (Data on file)
4. 4. Pairet M, Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In: Vane J, Botting J, Botting R, editors. Improved non-steroid anti-inflammatory drugs — COX-2 enzyme inhibitors. Lancaster: Kluwer Academic Publishers. In press
5. 5. Pargellis CA, Rogers S, Pav S. Inhibition of prostaglandin H synthase by meloxicam. Boehringer Ingelheim. (Data on file)
6. 6. Rainsford KD, Ying C, Gadd SJ. Pharmacology of meloxicam compared with other NSAIDS at inflamed sites: effects on cartilage proteoglycan metabolism, synovial production of prostaglandins and interleukins, and polymorph oxyradicals. Boehringer Ingelheim. (Data on file)
7. 7. Bassleer C, Franchimont P. Effects of meloxicam compared to acetylsalicylic acid in human articular chondrocytes. Boehringer Ingelheim. (Data on file)
8. 8. G. Engelhardt R. Bögel C. Schnitzler 1996 Meloxicam: influence on arachidonic acid metabolism. In vitro and in vivo findings — part 2 Biochem Pharmacol 51 29 38 8534265 10.1016/0006-2952(95)02110-8 1:CAS:528:DyaK28Xht1Gmug%3D%3D Engelhardt G, Bögel R, Schnitzler C, et al. Meloxicam: influence on arachidonic acid metabolism. In vitro and in vivo findings — part 2. Biochem Pharmacol 1996; 51: 29–38
9. 9. G. Engelhardt D. Homma K. Schlegel 1995 Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance Inflamm Res 44 423 33 8564518 10.1007/BF01757699 1:CAS:528:DyaK2MXptVKgt7w%3D Engelhardt G, Homma D, Schlegel K, et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995; 44: 423–33
10. 10. G. Engelhardt D. Homma C. Schnitzler 1995 Meloxicam: a potent inhibitor of adjuvant arthritis in the rat Inflamm Res 44 548 5 8788236 10.1007/BF01757360 1:CAS:528:DyaK28XmsVWluw%3D%3D Engelhardt G, Homma D, Schnitzler C. Meloxicam: a potent inhibitor of adjuvant arthritis in the rat. Inflamm Res 1995; 44: 548–5
11. 11. Mohr W, Lehmann H. Chondroneutrality of meloxicam in spontaneously occurring osteoarthrosis in rats and mice. Boehringer Ingelheim. (Data on file)
12. 12. Stichtenoth DO, Wagner B, Tsikas D, et al. Meloxicam does not inhibit platelet aggregation and renal prostaglandin E2 synthesis in healthy volunteers. Boehringer Ingelheim. (Data on file)
13. 13. Patoia L, Santucci L, Furno P, et al. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptoms evaluation in healthy volunteers. Br J Rheumatol. In press
14. 14. U. E. G. Busch 1990 Distribution of [ 14 C]meloxicam in joints of rats with adjuvant arthritis Drugs Exp Clin Res 16_2 49 52 Busch U, Engelhardt G. Distribution of [ 14 C]meloxicam in joints of rats with adjuvant arthritis. Drugs Exp Clin Res 1990; 16_(2): 49–52
15. 15. D. Türck U. Busch G. Heinzel 1996 Clinical pharmacokinetics of meloxicam Eur J Rheumatol Inflamm 15 23 30 Türck D, Busch U, Heinzel G, et al. Clinical pharmacokinetics of meloxicam. Eur J Rheumatol Inflamm 1996; 15: 23–30
16. 16. J. Schmid U. Busch G. Heinzel 1995 Meloxicam: pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects Drug Metab Dispos 23 11 1206 13 8591720 1:CAS:528:DyaK2MXpsFKmsr4%3D Schmid J, Busch U, Heinzel G, et al. Meloxicam: pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Dispos 1995; 23(11): 1206–13
17. 17. U. Busch G. Heinzel H. Narjes 1991 Effect of food on pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID) Agents Actions 32 52 3 2058471 10.1007/BF01983308 1:CAS:528:DyaK3MXhslOrt7Y%3D Busch U, Heinzel G, Narjes H. Effect of food on pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID). Agents Actions 1991 Jan; 32: 52–3
18. 18. D. Türck U. Busch G. Heinzel 1995 Effect of food on the pharmacokinetics of meloxicam after oral administration Clin Drug Invest 9 270 6 10.2165/00044011-199509050-00004 Türck D, Busch U, Heinzel G, et al. Effect of food on the pharmacokinetics of meloxicam after oral administration. Clin Drug Invest 1995 May; 9: 270–6
19. 19. Narjes H, Türck D, Busch U, et al. Tolerability and pharmacokinetics of meloxicam after i.m. administration. Boehringer Ingelheim. (Data on file)
20. 20. Busch U, Heinzel G, Narjes H, et al. Pharmacokinetics of meloxicam in patients with hepatic cirrhosis in comparison to healthy volunteers. Clin Drug Invest. In press
21. 21. Türck D, Schwarz A, Höffler D, et al. The pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis. A comparison with healthy volunteers. Boehringer Ingelheim. (Data on file)
22. 22. F. Degner U. Heinzel G. Busch 1994 Transsynovial kinetics of meloxicam [abstract] Scand J Rheumatol 98 121 Degner F, Heinzel U, Busch G, et al. Transsynovial kinetics of meloxicam [abstract]. Scand J Rheumatol 1994 Suppl. 98: 121
23. 23. Huskisson EC, Ghozlan R, Kurthen R, et al. A long term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheumatol. In press
24. 24. U. Busch G. Heinzel H. Narjes 1995 The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal antiinflammatory drug (NSAID), in man Eur J Clin Pharmacol 48 269 72 7589053 10.1007/BF00198310 1:CAS:528:DyaK2MXosl2msL4%3D Busch U, Heinzel G, Narjes H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal antiinflammatory drug (NSAID), in man. Eur J Clin Pharmacol 1995; 48: 269–72
25. 25. Busch U, Heinzel G, Narjes H, et al. Investigation of the interaction of meloxicam with Cimetidine, Maalox or aspirin. J Clin Pharmacol. In press
26. 26. F.O. Müller R. Schall A.C. Vaal de 1995 Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers Eur J Clin Pharmacol 48 247 51 7589049 10.1007/BF00198306 Müller FO, Schall R, de Vaal AC, et al. Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers. Eur J Clin Pharmacol 1995; 48: 247–51
27. 27. F.L. Degner G. Heinzel H. Narjes 1995 The effect of meloxicam on the pharmacokinetics of β-acetyl-digoxin Br J Clin Pharmacol 40 486 8 8703654 10.1111/j.1365-2125.1995.tb05794.x 1:STN:280:DyaK283ovVarsA%3D%3D Degner FL, Heinzel G, Narjes H, et al. The effect of meloxicam on the pharmacokinetics of β-acetyl-digoxin. Br J Clin Pharmacol 1995; 40: 486–8
28. 28. G. Hübner O. Sander F. Degner 1994 Lack of pharmacokinetic interaction of meloxicam with methotrexate in RA patients [abstract] Scand J Rheumatol 98 108 Hübner G, Sander O, Degner F, et al. Lack of pharmacokinetic interaction of meloxicam with methotrexate in RA patients [abstract]. Scand J Rheumatol 1994 Suppl. 98: 108
29. 29. B. Auvinet R. Ziller T. Appelboom 1995 A comparison of the onset and intensity of action of meloxicam ampoules and meloxicam capsules in sciatica Clin Ther 17 1078 90 8750399 10.1016/0149-2918(95)80086-7 1:STN:280:DyaK28zktlehsg%3D%3D Auvinet B, Ziller R, Appelboom T, et al. A comparison of the onset and intensity of action of meloxicam ampoules and meloxicam capsules in sciatica. Clin Ther 1995; 17: 1078–90
30. 30. Colberg K, Hettich M, Sigmund R, et al. The efficacy and tolerability of an 8 day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. Boehringer Ingelheim. (Data on file)
31. 31. Lemmel EM, Bolten W, Bourgos-Vargas R, et al. A doubleblind, randomized placebo controlled trial to evaluate the efficacy and safety of meloxicam 7.5 mg and 15 mg once daily in patients with rheumatoid arthritis. Boehringer Ingelheim. (Data on file)
32. 32. Huskisson EC, Narjes H, Bluhmki E. A 3 week double blind, randomized multicentre trial comparing the efficacy and tolerability of meloxicam, a new NSAID, in daily doses of 15 and 30 mg with piroxicam 20 mg in patients with rheumatoid arthritis. Boehringer Ingelheim. (Data on file)
33. 33. Wojtulewski JA, Schattenkirchner M, Barceló P, et al. A six months double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol. In press
34. 34. Ghozlan PR, Bernhardt M, Vélicitat P, et al. Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Br J Rheumatol. In press
35. 35. Lund B, Distel M, Bluhmki E. A double-blind randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Boehringer Ingelheim. (Data on file)
36. 36. Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a six-months, double-blind comparison with diclofenac sodium. Br J Rheumatol. In press
37. 37. Goei Thé H, Lund B, Distel M, et al. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Boehringer Ingelheim. (Data on file)
38. 38. Lindén b, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol. In press
39. 39. Hosie J, Distel M, Bluhmki E. A six months double-blind study to compare the efficacy, safety and tolerability of meloxicam and piroxicam in patients with osteoarthritis of the hip or knee. Boehringer Ingelheim. (Data on file)
40. 40. Bird HA, Bevis PJR, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatoid disease and mild renal impairment. Br J Rheumatol. In press
41. 41. Distel M, Mueller C, Bluhmki E, et al. Global analysis of safety of a new NSAID, meloxicam. Br J Rheumatol. In press
42. 42. H.E. Paulus 1988 FDA arthritis advisory committee meeting: serious gastrointestinal toxicity of nonsteroidal antiinflammatory drugs; drug-containing renal and biliary stones; diclofenac and carprofen approved Arthritis Rheum 31 1450 1 10.1002/art.1780311118 Paulus HE. FDA arthritis advisory committee meeting: serious gastrointestinal toxicity of nonsteroidal antiinflammatory drugs; drug-containing renal and biliary stones; diclofenac and carprofen approved. Arthritis Rheum 1988; 31: 1450–1
43. 43. J.R. Vane 1995 NSAIDS, cox-2 inhibitors, and the gut Lancet 346 1105 6 7564818 10.1016/S0140-6736(95)92770-0 1:STN:280:DyaK28%2FisF2mtA%3D%3D Vane JR. NSAIDS, cox-2 inhibitors, and the gut. Lancet 1995 Oct 21; 346: 1105–6